Catalent, Inc. (CTLT) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Catalent, Inc. (CTLT) Healthcare & Pipeline Overview

Catalent, Inc. provides development and manufacturing solutions for drugs, biologics, and consumer health products, operating across four segments. With a global presence and a focus on innovation, Catalent serves pharmaceutical, biotechnology, and consumer health companies, navigating a competitive landscape with a negative profit margin of -23.8%.

What Is the Investment Thesis for CTLT?

Catalent, Inc. presents a mixed investment thesis. The company's diverse service offerings across biologics, oral technologies, and clinical supply create multiple revenue streams. Catalent's role in drug development and manufacturing positions it to capitalize on the growing demand for specialized healthcare solutions. However, the company's negative profit margin of -23.8% raises concerns about operational efficiency and cost management. Upcoming catalysts include potential new partnerships and expansions in the cell and gene therapy space. Potential risks include increased competition, regulatory changes, and the need for continuous investment in technology and infrastructure. Investors should closely monitor Catalent's ability to improve profitability and manage its debt levels.

Based on FMP financials and quantitative analysis

CTLT Key Highlights

• Market capitalization of $11.5B indicates a significant presence in the drug manufacturing sector.
• Gross margin of 21.8% reflects the profitability of Catalent's core operations, but is offset by a negative profit margin.
• Beta of 1.16 suggests that Catalent's stock price is more volatile than the overall market.
• Catalent operates in four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services, providing diversified revenue streams.
• The company serves pharmaceutical, biotechnology, and consumer health companies, indicating a broad customer base.

Who Are CTLT's Competitors?

CTLT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CTLT's Key Strengths?

• Diverse service offerings across multiple segments.
• Global presence with a network of manufacturing facilities.
• Strong relationships with pharmaceutical and biotechnology companies.
• Expertise in advanced drug delivery technologies.

What Are CTLT's Weaknesses?

• Negative profit margin (-23.8%).
• High debt levels.
• Dependence on a limited number of key customers.
• Exposure to regulatory risks and compliance requirements.

What Could Drive CTLT Stock Higher?

• Potential new partnerships and collaborations with pharmaceutical companies.
• Expansion of capabilities in cell and gene therapy.
• Continued investment in advanced drug delivery technologies.
• Increasing demand for clinical supply services.

What Are the Key Risks for CTLT?

• Financial-distress signal — its Altman Z-Score of 1.60 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-25.3%) — the business is not currently generating profit on shareholder capital.
• Increased competition from other drug manufacturers.
• Regulatory changes and compliance requirements.
• Patent expirations and generic competition.
• Negative profit margin and high debt levels.
• Economic downturns and market volatility.

What Are the Growth Opportunities for CTLT?

• Expansion in Biologics: The biologics market is experiencing rapid growth, driven by the increasing demand for complex therapies. Catalent's Biologics segment, which includes cell and gene therapy manufacturing, is well-positioned to capitalize on this trend. Investing in capacity expansion and technological advancements in this area could drive significant revenue growth. The global biologics market is projected to reach $457 billion by 2025, offering a substantial opportunity for Catalent.
• Strategic Partnerships: Catalent can pursue strategic partnerships with pharmaceutical and biotechnology companies to expand its service offerings and geographic reach. Collaborating with companies developing novel therapies can provide Catalent with access to new markets and technologies. These partnerships can also lead to long-term contracts and recurring revenue streams. The market for pharmaceutical contract manufacturing is expected to reach $120 billion by 2028.
• Focus on Oral Delivery Technologies: The Oral and Specialty Delivery segment offers a range of technologies for formulation, development, and manufacturing. Focusing on innovative oral delivery solutions can provide a competitive advantage and attract new customers. Developing platforms for controlled release and bioavailability enhancement can address unmet needs in the pharmaceutical market. The global oral drug delivery market is projected to reach $100 billion by 2027.
• Growth in Clinical Supply Services: The Clinical Supply Services segment provides manufacturing, packaging, storage, and distribution for clinical trials. With the increasing number of clinical trials globally, there is a growing demand for these services. Catalent can expand its capabilities and geographic reach to capture a larger share of this market. The global clinical trial supply market is expected to reach $20 billion by 2026.
• Geographic Expansion: Catalent has a global presence, but there are opportunities to expand further into emerging markets. Investing in infrastructure and partnerships in regions with growing healthcare spending can drive revenue growth. Focusing on markets with increasing demand for pharmaceutical and biotechnology products can provide a competitive advantage. The emerging markets pharmaceutical market is projected to reach $650 billion by 2027.

What Opportunities Does CTLT Have?

• Expansion in the biologics market.
• Strategic partnerships with pharmaceutical and biotechnology companies.
• Growth in emerging markets.
• Increasing demand for clinical supply services.

What Threats Does CTLT Face?

• Intense competition from other drug manufacturers.
• Regulatory changes and compliance requirements.
• Patent expirations and generic competition.
• Economic downturns and market volatility.

What Are CTLT's Competitive Advantages?

• Specialized expertise in drug development and manufacturing.
• Advanced technology platforms for drug delivery.
• Global network of manufacturing facilities.
• Long-term relationships with pharmaceutical and biotechnology companies.

What Does CTLT Do?

Catalent, Inc., established in 2007 and headquartered in Somerset, New Jersey, is a global leader in providing advanced delivery technologies, development, and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products. The company operates through four key segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Biologics segment focuses on cell-line development, manufacturing of cell and viral-based gene therapies, and formulation for parenteral dose forms. The Softgel and Oral Technologies segment specializes in formulation, development, and manufacturing of soft capsules for prescription drugs, over-the-counter medications, dietary supplements, and animal health products. The Oral and Specialty Delivery segment offers a range of technologies for formulation, development, and manufacturing, along with integrated clinical development and commercial supply solutions. Lastly, the Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for clinical trials. Catalent serves a diverse clientele, including pharmaceutical, biotechnology, and consumer health companies, as well as those in animal health, medical devices, and cosmetics industries. With approximately 17,000 employees, Catalent continues to expand its capabilities and global footprint to meet the evolving needs of the healthcare industry.

What Products and Services Does CTLT Offer?

• Develop and manufacture solutions for drugs.
• Provide services for protein-based biologics.
• Offer cell and gene therapy development and manufacturing.
• Create consumer health product solutions.
• Provide formulation, development, and manufacturing services for soft capsules.
• Offer manufacturing, packaging, storage, and distribution for clinical trials.

How Does CTLT Make Money?

• Fee-for-service model for drug development and manufacturing.
• Contract manufacturing agreements with pharmaceutical and biotechnology companies.
• Revenue generated from four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.

What Industry Does CTLT Operate In?

Catalent operates within the drug manufacturing industry, a sector characterized by high regulatory scrutiny, intense competition, and continuous innovation. The market is driven by the increasing demand for specialized drug delivery systems and biologics. Catalent's focus on advanced technologies and comprehensive service offerings positions it to capitalize on these trends. Competitors like Becton, Dickinson and Company (BDX) and Walgreens Boots Alliance (WBA) also operate in the broader healthcare space, but Catalent's specialization in drug development and manufacturing provides a distinct advantage. The industry is expected to grow, driven by advancements in personalized medicine and the increasing prevalence of chronic diseases.

Who Are CTLT's Key Customers?

• Pharmaceutical companies
• Biotechnology companies
• Consumer health companies
• Animal health companies

Net sellingInsider Activity

The most recent 12 insider filings for Catalent, Inc. break down as 7 sales and 5 purchases. On net that is roughly 63K shares disposed (about $675K), a signal worth weighing alongside the fundamentals.

ROE -25%Key Financial Metrics

Return on equity for Catalent, Inc. stands at -25.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.52 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Catalent, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.60 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Catalent, Inc. revenue of about $4.99B for fiscal 2026, with EPS near $1.69. The estimate reflects 5 contributing analysts.

CTLT Valuation & Market Position

With a $11.5B market cap, Catalent, Inc. sits in the large-cap segment of the market. Relative to its peer group, CTLT's quantitative score of 48/100 is roughly in line with the peer average of 57/100.

CTLT Financials

CTLT Latest News

CTLT Analyst Consensus

CTLT MoonshotScore

What Investors Ask About Catalent, Inc. (CTLT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources